Oncology

Sakar Healthcare reported strong Q2FY27 consolidated revenue growth of 52% YoY to ₹87.42 crore and PAT surge of 149% to ₹11.31 crore. The company executed 69 oncology product contracts and has 33 tech

Sakar Healthcare reported Q2 FY27 revenue growth of 53% YoY to ₹8,741.61 lakhs with EBITDA surging 114% to ₹2,434.53 lakhs. PAT increased 149% YoY to ₹1,130.69 lakhs driven by better oncology mix and

Beta Drugs Limited reported H1 FY27 results with gross margins rising to 56.2% from 51.4% YoY. Branded Oncology segment grew 17% YoY, while Nivian brand recorded 75% growth and API business grew ~30%.

Beta Drugs Limited reported 29.2% YoY growth in consolidated revenue to ₹263.04 Cr for H1 FY27, with EBITDA at ₹61 Cr. The Board approved unaudited standalone and consolidated financial results for th